ImmunoPrecise Antibodies Ltd. filed a Form 6-K on June 4, 2024, confirming their status as a foreign private issuer and indicating they will file annual reports using Form 20-F. The filing is neutral with no significant changes disclosed, making it not significant for equity investors.